Breaking News

Novartis to Acquire MorphoSys AG for €2.7B

To gain pelabresib and ruxolitinib combo, which offers potential for first line of treatment in myelofibrosis with regulatory filing planned 2H24.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis has entered an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing oncology medicines, for €2.7 billion. The acquisition, subject to customary closing conditions, further expands Novartis’ oncology pipeline as well as its global footprint in hematology.   Upon completion, Novartis will own pelabresib (CPI-0610), a novel treatment option with a well-tolerated safety profile provided in combination wit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters